Recombinant, Stabilized Pre-F Respiratory Syncytial Virus (RSV) Vaccine (MAXVAX Biotechnology)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameRecombinant, Stabilized Pre-F Respiratory Syncytial Virus (RSV) Vaccine (MAXVAX Biotechnology)
Drug Alias NameMKK900
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMaxvax Biotechnology LLC
China Registration ClassN/A

Develop Information

Active CompaniesMaxvax Biotechnology LLC
Inactive CompaniesN/A
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A